-

agilon health, inc. (AGL) Stockholder Alert: Robbins LLP Reminds Investors of AGL Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of (a) all persons and entities that purchased or otherwise acquired agilon health, inc. (NYSE: AGL) common stock between January 9, 2023 and January 4, 2024, and (b) all persons and entities that purchased or otherwise acquired agilon health, inc. common stock in connection with the Company's May 2023 secondary public offering ("SPO"). Agilon generates profits from reducing medical expenditures.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating the Allegations that agilon health, inc. (AGL) Misled Investors Regarding Medical Costs

According to the complaint, during the class period and in the SPO materials, defendants misled investors about agilon’s medical costs by: (1) touting the Company’s purported visibility into utilization trends and medical costs; (2) failing to disclose increased medical costs that agilon had incurred prior to and during the class period due to higher utilization of healthcare by MA patients; (3) falsely stating that its IBNR Reserve was adequate; (4) making false and misleading statements about the effectiveness of its business model; (5) issuing overly optimistic financial guidance; and (6) issuing risk disclosures that were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities.

The truth about the higher medical costs emerged as the Company reported lower-than-expected financial results and lower expectations for future revenue. As a result, the price of the Company's share price fell, harming investors.

What Now: You may be eligible to participate in the class action against agilon health, inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 20, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against agilon health, inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:AGL

Release Summary
Robbins LLP is Investigating the Allegations that agilon health, inc. (AGL) Misled Investors Regarding Medical Costs
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder Rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.On January 8, 2026, Beta Bioni...

Robbins LLP is Investigating Allegations that the Officers and Directors of Simulations Plus, Inc. (SLP) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the pharmaceutical, biotechnology, and chemical industries. On June 11, 2025, Simulations Plus announced preliminary third-quarter fiscal 2025 revenue and updated its full-year fiscal 2025 rev...

Shareholder Notice: Robbins LLP Informs Investors of the Lucid Group, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Lucid Group, Inc. (NASDAQ: LCID) securities between February 25, 2026 and April 13, 2026. Lucid is a technology company that designs, develops, manufactures, and sells electric vehicles (“EVs”), EV powertrains, and battery systems.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Alleg...
Back to Newsroom